"Official medicines" is the best online drugstore.

World’s leading meds delivered to your door – and you don’t even need a prescription! Only certified, first class drugs on offer! Buy more and spend less with our great discount system.

The meds you need, reliable and hassle free! Top products of top brands.

The only pharmacy shop you will ever need! Approved drugs available without prescription. Best deals, unmatched service and shipping. 100% safe!

(VEN-luh-fax-EEN)
Effexor
Tablets
25 mg
Tablets
37.5 mg
Tablets
50 mg
Tablets
75 mg
Tablets
100 mg
Effexor XR
Capsules, extended-release
37.5 mg
Capsules, extended-release
75 mg
Capsules, extended-release
150 mg
Class: Antidepressant

  Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.

  Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).

  Contraindications Concomitant use with MAOIs.

  Route/Dosage

Depression

ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).

ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.

Generalized Anxiety Disorder

ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.

  Interactions

Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.

  Lab Test Interferences None well documented.

  Adverse Reactions CARDIOVASCULAR: Hypertension; migraine; vasodilation; tachycardia; postural hypotension. CNS: Insomnia; somnolence; anxiety; headache; dizziness; nervousness; tremor; asthenia; abnormal dreams; hypertonia; paresthesia; agitation; confusion; abnormal thinking; depersonalization; twitching. DERMATOLOGIC: Sweating; rash; pruritus. EENT: Blurred vision; taste perversion; tinnitus; mydriasis. GI: Nausea; anorexia; dry mouth; constipation; dysphagia; diarrhea; vomiting; dyspepsia; flatulence; weight loss. GU: Abnormal ejaculation or orgasm; dysuria; hematuria; increased BUN; vaginitis; decreased libido; urinary retention; impotence; urinary frequency; anorgasmia (female); impaired urination; orgasm disturbance; menstrual disorder. HEMATOLOGIC: Ecchymosis. HEPATIC: Increased LFT results and bilirubin. METABOLIC: Peripheral edema; weight gain. RESPIRATORY: Dyspnea. OTHER: Pharyngitis; infection; chills; chest pain; trauma; yawn.

  Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy in patients < 18 yr not established. Elderly: Take extra care when increasing dose in elderly patients. Special Risk Patients: Use drug with caution in patients with history of seizure, mania, suicidal tendencies, drug abuse, or dependence. Hepatic or Renal Impairment: Reduction of dose may be necessary. Use drug with caution. Hypertension: Regular monitoring of BP is recommended. Venlafaxine is associated with sustained but small increases in BP (usually associated with doses > 300 mg/day). Discontinuation: After 1 wk of therapy, dosage requires tapering if discontinuing; after 6 wk of treatment, taper over 2-wk period.

PATIENT CARE CONSIDERATIONS

  Administration/Storage

  • Administer with meals.
  • Store at room temperature in tight container.

  Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Establish baseline weight.
  • Establish baseline serum cholesterol level.
  • After 4 to 6 wk of therapy, reevaluate long-term usefulness.
  • Monitor BP at least twice a week.
OVERDOSAGE: SIGNS & SYMPTOMS
  Somnolence, sinus tachycardia

  Patient/Family Education

  • Advise patient to avoid intake of alcoholic beverages and other CNS depressants.
  • Tell patient to report any rash or hives.
  • Advise patient to report to health care provider any other prescription or otc drugs that may be taken.
  • Advise patient to take sips of water frequently, to suck on ice chips or sugarless hard candy, or sugarless chewing gum if dry mouth occurs.
  • Instruct patient to use caution when driving or performing other tasks that require mental alertness or coordination.
  • Advise patient to avoid prolonged exposure to sunlight or sunlamps or wear protective clothing; photosensitivity may occur.
  • Advise patients to notify health care provider if pregnant, intending to become pregnant during therapy, or breastfeeding.

Popularity: 6% [?]


If you're still unable to find appropriate information in the article, please use search form below